Lesinurad (Zurampic): What Happened, and What to Take Instead

Your kidneys are supposed to be the exit door for uric acid. In most people with gout, that door is held partly shut: the kidneys keep pulling uric acid back into the blood instead of letting it leave. That reabsorption runs through a protein in the kidney tubules called URAT1, and lesinurad was built to block it. Think of it as reopening a drain that had been left half-closed, so more uric acid washes out with your urine ².

That makes lesinurad a uricosuric, the same broad family as probenecid. What set it apart was a strict rule written into its approval: it was only ever cleared for use alongside a xanthine oxidase inhibitor, meaning allopurinol or febuxostat, for people who had not reached target on one of those drugs alone ². It was never a solo act. It was the second instrument, added when the first was not quite enough.

Here is the part worth being precise about, because the internet is vague on it. Lesinurad was withdrawn from the US market by the manufacturer, though it technically remains approved by the FDA ³. It was later pulled from all markets. The reason was mostly commercial, not a dramatic safety recall: it sold poorly, driven by the fact that you had to take it on top of another drug and by lingering concerns about its effect on the kidneys ⁴.

So no, you were not taken off a dangerous drug in the night. A medicine that worked for some people simply stopped being manufactured because it never found enough of a market to justify keeping it. That is a business decision, and it is nobody's fault, least of all yours.

The reason lesinurad only ever came at one strength, 200 mg a day, was a safety limit rather than a marketing choice. Higher doses raised the risk of harming the kidneys, so 200 mg was set as a ceiling that was not to be crossed ². In the trials, a small share of people on lesinurad saw their serum creatinine, a marker of kidney strain, more than double, and in a fraction of those it did not fully recover ².

That signal is exactly why it always had to ride alongside a xanthine oxidase inhibitor and why doctors kept an eye on kidney bloodwork. It is also part of why it never became popular. None of this should frighten anyone who took it and did fine; it simply explains the caution that surrounded the drug from the start.

The goal has not changed. Whatever you were reaching for with lesinurad, the target is still a serum urate below 6 mg/dL, held there long enough for the crystals to dissolve and the flares to stop ¹. Losing one medicine does not lose you the target, and there is more than one road back to it.

If you never fully optimized allopurinol, that is usually the first place to look. It is the guideline's preferred first-line urate-lowering therapy, including for people with moderate-to-severe kidney disease ¹. The intended pattern is to start at a low dose and titrate upward until urate reaches target ¹, so it is worth asking whether yours was ever carried all the way there. Febuxostat is the alternative in the same xanthine-oxidase family. And if a uricosuric is what suited you, probenecid does the same kidney-flushing job lesinurad did, typically started low at 500 mg once or twice daily and titrated up ³.

One caveat matters here, given how much of lesinurad's story was about kidneys. If your kidney function is reduced, at CKD stage 3 or worse, the guideline strongly recommends a xanthine oxidase inhibitor over probenecid ³. So the uricosuric road is not open to everyone, and your kidney numbers are part of what decides it.

One thing worth knowing before you assume the answer is a second drug: when a first xanthine oxidase inhibitor has been pushed to its limit and urate is still too high, the ACR actually leans toward switching to a different one over stacking a uricosuric on top ³. Combination therapy has its place, but it is not automatically the next step. That is a conversation to have with your clinician rather than a rule to apply yourself.

Do not simply let your urate-lowering treatment lapse because one part of it vanished. When you stop lowering uric acid, the crystals start reforming and the quiet joint damage picks back up, often before you feel a single flare. The safe move is to book time with the clinician who prescribed it and map out a replacement, not to wait and see.

Bring your most recent urate number if you have one. It tells your doctor how far you were from target and whether the answer is a better-optimized allopurinol dose, a switch, or a fresh uricosuric like probenecid. You lost a medicine, not the plan.